[
  {
    "ts": null,
    "headline": "The Dow Industrials Have Tilted More Toward Financials",
    "summary": "Since the Dow hit 40000 for the first time nearly two years ago, the index has grown heavier in financial stocks and trimmed back its exposure to the health-care sector.  Much of this is due to the recent outperformance of financial stocks like Goldman Sachs and JPMorgan, and the relative underperformance of stocks like Merck and UnitedHealth.  Two new stocks have come into the index—Nvidia and Sherwin-Williams—during the Dow’s \"40-something\" years.",
    "url": "https://finnhub.io/api/news?id=06930a70dd09668215393e03705201dbcd916e02b7ac90311e9d89e7cc591265",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770412502,
      "headline": "The Dow Industrials Have Tilted More Toward Financials",
      "id": 138379474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Since the Dow hit 40000 for the first time nearly two years ago, the index has grown heavier in financial stocks and trimmed back its exposure to the health-care sector.  Much of this is due to the recent outperformance of financial stocks like Goldman Sachs and JPMorgan, and the relative underperformance of stocks like Merck and UnitedHealth.  Two new stocks have come into the index—Nvidia and Sherwin-Williams—during the Dow’s \"40-something\" years.",
      "url": "https://finnhub.io/api/news?id=06930a70dd09668215393e03705201dbcd916e02b7ac90311e9d89e7cc591265"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push",
    "summary": "PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.",
    "url": "https://finnhub.io/api/news?id=be58eb620982563eb1157d3e8cc281873da85c5a40b01bbdcb619fd5233daad0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770393960,
      "headline": "Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push",
      "id": 138376809,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.",
      "url": "https://finnhub.io/api/news?id=be58eb620982563eb1157d3e8cc281873da85c5a40b01bbdcb619fd5233daad0"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Subdued 2026 Outlook: What it Means After Q4 Results?",
    "summary": "MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.",
    "url": "https://finnhub.io/api/news?id=5b136ac6391a3dec6d665fb65169bf4e7dc20719168bc6893babb76d3e3172b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770393840,
      "headline": "Merck's Subdued 2026 Outlook: What it Means After Q4 Results?",
      "id": 138376827,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.",
      "url": "https://finnhub.io/api/news?id=5b136ac6391a3dec6d665fb65169bf4e7dc20719168bc6893babb76d3e3172b3"
    }
  },
  {
    "ts": null,
    "headline": "Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic",
    "summary": "USMV and other low-volatility ETFs gain appeal as an AI-driven tech rout wipes $1T, spikes VIX, and fuels rotation into staples and value sectors.",
    "url": "https://finnhub.io/api/news?id=004d2a54ba933d557c0e25a45c8ed721ecbeed95b385dd6f0bfb572e198fa10b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770388080,
      "headline": "Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic",
      "id": 138376826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "USMV and other low-volatility ETFs gain appeal as an AI-driven tech rout wipes $1T, spikes VIX, and fuels rotation into staples and value sectors.",
      "url": "https://finnhub.io/api/news?id=004d2a54ba933d557c0e25a45c8ed721ecbeed95b385dd6f0bfb572e198fa10b"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Roundup: Risk Off",
    "summary": "Wall Street Roundup: Risk Off",
    "url": "https://finnhub.io/api/news?id=5db7425b274994beeeb97d33fc288fa8b00a21523c834bb7e38e48e0e9cf58d1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770384300,
      "headline": "Wall Street Roundup: Risk Off",
      "id": 138377368,
      "image": "",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5db7425b274994beeeb97d33fc288fa8b00a21523c834bb7e38e48e0e9cf58d1"
    }
  },
  {
    "ts": null,
    "headline": "Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC",
    "summary": "The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases,",
    "url": "https://finnhub.io/api/news?id=51aa6c69abbf11384a4a7670810b8fc45f388b09d1eb6c0b0ee9d3cf22e7e255",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770382800,
      "headline": "Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC",
      "id": 138374429,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of patient enrolment remain on track for the first quarter and the third quarter of CY2026, respectively SYDNEY, AUSTRALIA, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases,",
      "url": "https://finnhub.io/api/news?id=51aa6c69abbf11384a4a7670810b8fc45f388b09d1eb6c0b0ee9d3cf22e7e255"
    }
  },
  {
    "ts": null,
    "headline": "White House’s online service for drug sales debuts with limited impact on prices",
    "summary": "Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many Americans whose medications are covered by insurance.",
    "url": "https://finnhub.io/api/news?id=9848a56c7fffd6e2975f109c5718388239a7e1122dfb3baf999ba965a90015d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770379680,
      "headline": "White House’s online service for drug sales debuts with limited impact on prices",
      "id": 138376812,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many Americans whose medications are covered by insurance.",
      "url": "https://finnhub.io/api/news?id=9848a56c7fffd6e2975f109c5718388239a7e1122dfb3baf999ba965a90015d2"
    }
  },
  {
    "ts": null,
    "headline": "Merck KGaA Names Hein To Steer Electronics Deeper Into Semiconductors",
    "summary": "Merck KGaA (XTRA:MRK) has appointed Benjamin Hein as chief executive of its Electronics business sector. Hein will also join the executive board, succeeding Kai Beckmann. The move highlights Merck's continued focus on semiconductors and on reshaping its Electronics unit. For you as an investor, this appointment is part of Merck KGaA's efforts to position its Electronics business more firmly within the semiconductor supply chain. The company already spans healthcare, life science and...",
    "url": "https://finnhub.io/api/news?id=2390483fc14d71784effc1be8f9965575b50c006206cc4fd63b527a38f604796",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770368824,
      "headline": "Merck KGaA Names Hein To Steer Electronics Deeper Into Semiconductors",
      "id": 138372944,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck KGaA (XTRA:MRK) has appointed Benjamin Hein as chief executive of its Electronics business sector. Hein will also join the executive board, succeeding Kai Beckmann. The move highlights Merck's continued focus on semiconductors and on reshaping its Electronics unit. For you as an investor, this appointment is part of Merck KGaA's efforts to position its Electronics business more firmly within the semiconductor supply chain. The company already spans healthcare, life science and...",
      "url": "https://finnhub.io/api/news?id=2390483fc14d71784effc1be8f9965575b50c006206cc4fd63b527a38f604796"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s ENFLONSIA Approval Adds To Respiratory Portfolio And Valuation Story",
    "summary": "Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA, its RSV preventive therapy for infants. The authorization expands Merck's presence in the respiratory and infectious disease space in Canada. The company has also been adding to its respiratory and infectious disease portfolio through recent launches and acquisitions. For investors watching Merck beyond its oncology franchise, this news highlights another piece of the broader story. The stock trades at $119.75, with returns of...",
    "url": "https://finnhub.io/api/news?id=99e42e43c707884b02adff28068dc1f662dcad5f8bcf0d9be205ef0860dec16a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770343770,
      "headline": "Merck’s ENFLONSIA Approval Adds To Respiratory Portfolio And Valuation Story",
      "id": 138371230,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) received Health Canada approval for ENFLONSIA, its RSV preventive therapy for infants. The authorization expands Merck's presence in the respiratory and infectious disease space in Canada. The company has also been adding to its respiratory and infectious disease portfolio through recent launches and acquisitions. For investors watching Merck beyond its oncology franchise, this news highlights another piece of the broader story. The stock trades at $119.75, with returns of...",
      "url": "https://finnhub.io/api/news?id=99e42e43c707884b02adff28068dc1f662dcad5f8bcf0d9be205ef0860dec16a"
    }
  }
]